Highlights •PKCλ/ι is required for Paneth cell differentiation •PKCλ/ι reduces EZH2 stability and promotes Atoh1 and Gfi1 expression •PKCλ/ι induces intestinal epithelial cell survival through the repression of JNK •PKCλ/ι loss enhances intestinal inflammation and cancer
A promising new target for future drugs to treat inflammatory bowel disease (IBD) has been found. The study also indicates that another protein, protein kinase C (PKC) λ/ι, may serve as a biomarker of IBD severity. “The intestine is protected by specialized cells, called Paneth cells, that secrete antimicrobial peptides,” said Jorge Moscat, Ph.D., deputy director and professor in the NCI-designated Cancer Center...
Read More
Recent Comments